ABCB1 and glioblastoma: In glioblastoma patients, currently available EGFR inhibitors do not provide a survival benefit but could be used to overcome blood-brain barrier ABCB1/ABCG2-mediated drug resistance via transporter internalization/degradation (de Gooijer et al., 2018b; Kim et al., 2019b).